Prime Highlights
- Marksans Pharma will acquire 100% of QliniQ BV for €7.5 million to strengthen its presence in regulated European markets.
- The acquisition gives Marksans direct sales, marketing, and distribution capabilities in the European Union.
Key Facts
- Marksans Pharma is an Indian pharmaceutical company with a growing presence in global regulated markets.
- QliniQ reported revenue of €9.35 million and net profit of €1.01 million for the year ended December 2025, while remaining debt-free.
Background
Marksans Pharma Ltd. said it has agreed to acquire QliniQ BV, a pharma company based in the Netherlands, for € 7.5 million. The move is part of their strategy to bolster its position within regulated European markets, the company noted.
The company has signed a definitive agreement to acquire the entire share capital of QliniQ. Marksans Pharma said the deal will support its forward-integration plans by giving it direct sales, marketing, and distribution capabilities across the European Union. The merger is projected to enhance the customer and healthcare access channels of the business.
QliniQ has a range of specialised pharmaceutical products and medical devices for areas such as women’s health, dermatology, and respiratory treatments. QliniQ has created a robust distribution network in the Netherlands through wholesalers, pharmacies, hospitals, and insurance-led tender channels.
The financial results of QliniQ for the fiscal year ended December 2025 amounted to €9.35 million in revenue and a net profit of €1.01 million. The company achieved revenue growth at a compound annual growth rate of nearly 41% between FY23 and FY25 while maintaining a debt-free balance sheet.
Marksans Pharma Chairman and Managing Director Mark Saldanha said the acquisition would provide the company with direct access to the Dutch market and strengthen its ability to commercialise both existing and future products across regulated European markets.
The company believes the acquisition will support its long-term growth plans and help expand its international presence. Shares of Marksans Pharma were trading 0.48% lower at ₹245.02 on Monday. Despite the decline, the stock has gained about 36% so far in 2026